New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
09:38 EDTNVAX
theflyonthewall.com: Novavax 6.8M share Secondary priced at $3.30
Piper Jaffray & Co. and Lazard Capital Markets LLC are acting as joint book running managers. :theflyonthewall.com



News For NVAX From The Last 14 Days
Check below for free stories on NVAX the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2010
16:37 EDTNVAX
theflyonthewall.com: On The Fly: U.S. Market Wrap-Up for Monday 2/8

Subscribe for More Information
:theflyonthewall.com
12:42 EDTNVAX
theflyonthewall.com: Novavax reports new data from trivalent VLP vaccine study
Novavax announced new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains. The study enrolled 241 subjects, including 221 who were randomized to receive either VLP vaccine at 15 mcg or 60 mcg doses or a placebo and 20 subjects who received a licensed inactivated influenza vaccine. In continued evaluation of the May 2009 clinical study, Novavax tested volunteers for NAI against H3N2/Brisbane and B/Florida components of the vaccine before and after immunization. The results showed that 50 to 73% of the volunteers immunized with the Novavax VLP vaccine had a 4-fold increase in the antibody that blocks neuraminidase activity. In contrast, only 1 of 19 volunteers that received the TIV showed a 4-fold rise for NAI. There was no 4-fold rise in volunteers that received placebo. :theflyonthewall.com
06:08 EDTNVAX
theflyonthewall.com: Novavax discontinues negotiations with Rovi Pharmaceuticals

Subscribe for More Information
:theflyonthewall.com